July 28 (Reuters) – Bristol-Myers Squibb Co reported
disappointing second-quarter sales of its Yervoy melanoma
treatment on Thursday, raising concerns about the long-term
prospects for one of its…
The post UPDATE 3-Bristol-Myers shares hit by decline of Yervoy melanoma drug appeared first on NASDAQ.